

# The Value of Clinical, Laboratory and Brain CT Scan Findings in Methanol Toxicity

Leila Etemad<sup>1,2</sup>, Amir Ali Moodi Ghalibaf<sup>3</sup>, Ali Sadr<sup>4</sup>, Masoud Pezeshki Rad<sup>5</sup>, Majid Khadem-Rezaian<sup>6</sup>, Amir Behforouz<sup>4,5</sup>, Setareh Azarkar<sup>3</sup>, Asieh Karimani<sup>7</sup>, Hossein Ghaffari<sup>8</sup>, Mohammad Moshiri<sup>9\*</sup>

<sup>1</sup> Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>2</sup> Department of Pharmaceutical Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>3</sup> Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>4</sup> Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>5</sup> Department of Radiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>6</sup> Department of Community Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>7</sup> Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>8</sup> Organ Transplant Superspecialty Montaserieh Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>9</sup> Medical Toxicology Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Received: 05 Mar. 2025; Accepted: 21 Apr. 2026

**Abstract-** Methanol poisoning is a severe intoxication that can be fatal. This study aimed to determine the association between clinical and paraclinical findings, particularly brain radiological findings, and the risk of mortality in methanol-poisoned patients. This retrospective cross-sectional study was conducted at the CTD-IRH-MUMS, Mashhad, Iran, from March 2019 to March 2021. Medical and demographic data of adult patients with a confirmed diagnosis of methanol poisoning who had undergone a brain computed tomography (CT) scan were included. A total of 45 methanol-poisoned patients were enrolled in the study, including 36 men (80%) with a mean age of  $34.32 \pm 13.20$  years. Among them, 15 patients (33.3%) had at least one abnormal finding on their brain CT scans. The most frequent finding was diffuse cerebral hemorrhage ( $n=12$ , 26.7%), followed by subcortical white matter changes ( $n=9$ , 20%), and putaminal hypodensities ( $n=7$ , 15.6%). Although abnormal brain CT findings were associated with a higher risk of mortality ( $OR=4.929$ ,  $P=0.019$ ), they were not related to any specific type of CT findings. A Glasgow Coma Scale (GCS) score  $<9$  ( $OR=0.445$ ,  $P=0.003$ ), respiratory rate  $>19$  breaths/min ( $OR=2.675$ ,  $P=0.006$ ), serum creatinine level  $>1.8$  mg/dL ( $OR=6.258$ ,  $P=0.009$ ), potassium level  $>4.3$  mEq/L ( $OR=3.672$ ,  $P=0.006$ ), glucose level ( $OR=1.011$ ,  $P=0.019$ ), bicarbonate level  $<11.4$  mEq/L ( $OR=0.872$ ,  $P=0.003$ ), and pH  $<7.11$  ( $OR=0.001$ ,  $P=0.003$ ) were predictors of mortality with acceptable sensitivity and specificity. Lower GCS, PCO<sub>2</sub>, and HCO<sub>3</sub> levels, along with higher blood pressure, were associated with a higher incidence of pathological brain CT findings. Physicians should consider acidosis, tachypnea, decreased consciousness, and elevated blood glucose and creatinine levels as predictors of mortality or pathological brain CT findings.

© 2026 Tehran University of Medical Sciences. All rights reserved.

*Acta Med Iran* 2026;64(7):410-421.

<https://doi.org/10.18502/acta.v64i7.22415>

**Keywords:** Methanol; Poisoning; CT scan; Sensitivity and specificity; Mortality

## Introduction

Methanol, also known as methyl alcohol, is an essential organic chemical widely used as an industrial,

agricultural, and household agent (1). The potentially lethal dose of methanol is reported to be 30 to 240 mL, or 1 g/kg. Methanol exerts its toxic effects through metabolism to formaldehyde and subsequently to formic

**Corresponding Author:** M. Moshiri

Medical Toxicology Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran  
Tel: +98 5138598973, E-mail address: Moshirim@mums.ac.ir

Copyright © 2026 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (<https://creativecommons.org/licenses/by-nc/4.0/>). Non-commercial uses of the work are permitted, provided the original work is properly cited

acid, which eventually leads to oxidative injury (2).

Most reported cases of methanol poisoning result from accidental or suicidal ingestion (3,4). The mortality rate in hospitalized patients has ranged from 18% to 30% in previous studies (5-7). A recent cross-sectional study of 795 patients in Iran reported a mortality rate of 10.6% among methanol-poisoned patients during the COVID-19 pandemic (8). The surge of COVID-19 and increased availability of alcohol, besides misinformation, led to an outbreak of methanol poisoning cases, which were likely caused by gargling or drinking alcohol (8-12).

Although in the first 12 to 24 hours post-exposure, presentation can be normal, the most common signs of acute methanol poisoning include a variety of symptoms based on the amount of methanol administration such as weakness, blurred vision, nausea, vomiting, epigastric pain, central nervous system (CNS) depression, stupor, coma, and death (13,14). Considering the neurotoxic effects of methanol metabolites, neuroimaging can play a key role in ruling out differential diagnoses.

Regarding the neurotoxic effects of methanol metabolites on the nervous system, neuroimaging can play a key role to rule out differential diagnoses. Some non-specific findings were reported in the brain imaging of methanol-poisoned patients (15-20). One of the most finding is putaminal necrosis, which may lead to common complication of methanol poisoning, motor dysfunction in survivors (21,22). However, there are a few reports of a relationship between this finding and the mortality of patients.

We conducted the present study to describe an association between the brain CT findings of acute methanol intoxication and the mortality incidence. We also evaluated the predictive value of clinical, laboratory and pathological finding in brain CT scan and mortality rate of methanol poisoned cases.

## Materials and Methods

### Study design and setting

This retrospective cross-sectional study was designed to investigate the clinical, laboratory, and brain radiological findings in methanol-poisoned patients referred to a tertiary care center in northeastern Iran, the Clinical Toxicology Department of Imam Reza Hospital, affiliated with Mashhad University of Medical Sciences (CTD-IRH-MUMS), Mashhad, Iran, from March 2019 to March 2021. All patients over 18 years old with a definite diagnosis of methanol poisoning who underwent a brain computed tomography scan (CT scan) were included in the study by census sampling. Patients who expired

before diagnostic investigations or had incomplete medical documentation were excluded from the final analysis. The study protocol was approved by the Mashhad University of Medical Sciences Ethics Committee, Mashhad, Iran (IR.MUMS.MEDICAL.REC.1399.471). The patient information was kept confidential during the investigation by adding codes and deleting their names. All methods were carried out in accordance with the relevant guidelines and regulations.

### Data collection

Data were collected using a checklist and evaluating the patient's medical records, laboratory data, and radiologic workup. Demographic characteristics (sex, age, past medical history, admission outcome), type of poisoning (intentional or unintentional), and details regarding the toxic alcohol (type, packaging, and source of supply) were collected. Admission clinical findings including pulse rate (PR), systolic blood pressure (SBP), diastolic blood pressure (DBP), respiratory rate (RR), visual impairment, visual acuity, pupillary status, and Glasgow Coma Scale (GCS) score were recorded. Laboratory data, including blood ethanol and methanol levels, serum levels of creatinine, urea, sodium, potassium, and calcium, blood glucose (BG), blood gas status, and brain CT findings, were gathered and analyzed. CT scans were independently interpreted by two experts. If there was a disagreement in their reports, the brain CT scan was evaluated by the third expert radiologist. All brain CT scans were performed using a NeuViz Classic 16-slice CT scanner system with a standard protocol.

### Statistical analysis

Statistical analysis was conducted using SPSS software version 11.5 (SPSS Inc., Chicago, USA –version 11.5). Descriptive statistics for the demographic characteristics were presented by the median, maximum, minimum, mean, and standard deviation (SD) for quantitative variables and frequency (percentage) for qualitative variables. Fisher's exact test and logistic regression analysis were used to investigate relationships between qualitative variables.

The comparison of quantitative data was performed by independent sample t-test or Mann-Whitney U tests.

For each clinical and laboratory variable, receiver operating characteristic (ROC) curves for mortality and CT findings were generated, and the area under the curve (AUC) with a 95% confidence interval (95% CI) was calculated. Then, the diagnostic sensitivity and specificity

using MedCalc software (version 22.001) were estimated. Variables with AUC>0.7 were identified as potential diagnostics. A *P* less than 0.05 was considered as the significance level.

## Results

Based on the study inclusion and exclusion criteria, 45 methanol-poisoned patients were enrolled, of whom 36 (80%) were male. The mean age of the patients was 34.32±13.20 years (range, 18-72 years). Thirty-nine patients (86.7%) had consumed homemade alcohol, 17 (37.8%) obtained it from bootleggers, and 38 (84.4%) stated that there was no registered packaging for the consumed alcohol (Table 1).

Although 36 patients (80%) had no past medical history, hypertension was the most frequent underlying medical condition in the study population (*n*=3, 6.7%) (Table 2).

Visual impairment (*n*=26, 57.8%), loss of consciousness (*n*=25, 55.6%), and nausea and vomiting (*n*=21, 46.7%) were the most frequent chief complaints, in descending order. While 16 patients (35.6%) with visual impairment reported blurred vision, normal visual acuity was documented in 13 (28.9%) patients.

Pupillary mydriasis was observed in most patients (*n*=14, 31.1%) (*n*=14, 31.1%). The analyzed data revealed that 16 patients (35.6%) expired (Table 2).

The GCS score on admission was 13 to 15 in 19 patients (48.7%). There was a significant difference between GCS levels in survivors and non-survivors (*P*<0.001) groups and the lower GCS was significantly associated with a higher mortality rate (OR=0.445, CI: 0.260-0.763, *P*=0.006) (Table 3). The motor component of the GCS was more critical than the other two components. A GCS score of less than 9 predicted mortality with high sensitivity and specificity (Table 4).

Among the vital signs, only the respiratory rate was significantly associated with mortality (OR=2.675, 95% CI: 1.325-5.395, *P*=0.006) (Table 3). Furthermore, patients who presented with dyspnea had a significantly higher mortality rate (OR=20.0, 95% CI: 2.009-199.73, *P*=0.005). A respiratory rate of more than 19 cycles/min could predict mortality with high sensitivity and specificity (Table 4).

The mean blood methanol level was 21.12±33.11 mg/dL, the blood ethanol level was 19.94±20.96 mg/dL, and the mean pH was 7.20±0.21 (Table 5). The non-survivors' cases had higher creatinine, potassium, and glucose blood levels, and lower PH, and HCO<sub>3</sub> serum levels (Table 5). Higher levels of potassium (OR=3.672,

95% CI: 1.443-9.345, *P*=0.006), glucose (OR=1.011, 95% CI: 1.002-1.020, *P*=0.019), and creatinine (OR=6.258, 95% CI: 1.59-24.58, *P*=0.009), along with lower levels of HCO<sub>3</sub> (OR=0.872, 95% CI: 0.797-0.953, *P*=0.003) and pH (OR=0.001, 95% CI: 0.00-0.109, *P*=0.003), were associated with a higher risk of mortality (Tables 4 and 5). However, the exact the blood PCO<sub>2</sub> level was not a suitable predictor of mortality. Based on the data recorded on patients' documents, 18(40%) cases underwent emergency dialysis, and 7(15.6%) of them underwent the second time hemodialysis. The median time of the first dialysis was 14 hours (IQR=6-24) post-hospitalization, and the median time of the second dialysis was 24 hours (IQR=12-46) post-hospitalization.

Among the 45 brain CT scans evaluated, 15 patients (33.3%) had at least one abnormal finding on tomography. The most frequent abnormal findings were diffuse cerebral hemorrhage (*n*=12, 26.7%), subcortical white matter changes (WMCs) (*n*=9, 20%), and putaminal hypodensities (*n*=7, 15.6%). Other less prevalent abnormalities included cerebellar hypodensity, as well as intraventricular, intracranial, and putaminal hemorrhages (Table 6).

Although logistic regression analysis predicted the mortality rate of methanol poisoning based on the presence of abnormal brain CT findings (OR=4.929, 95% CI: 1.297-18.733; *P*=0.019), there was no significant relationship between any specific type of brain CT finding and mortality (*P*>0.05) (Table 6). The frequency of various types of brain CT findings was not different in both sexes, patients with and without convulsion, nausea and vomiting, and respiratory distress.

The presence of significant pathological findings on brain CT was more likely in patients with higher systolic blood pressure (OR=1.037, 95% CI: 1.003-1.072, *P*=0.035), lower PCO<sub>2</sub> (OR=0.940, 95% CI: 0.8920.991, *P*=0.022), and lower HCO<sub>3</sub> levels (OR=0.923, 95% CI: 0.854-0.997, *P*=0.042) (Table 7). Hypocapnia (PCO<sub>2</sub><32.4 mmHg) was a sensitive indicator of the presence of various pathological findings on brain CT scans in methanol-poisoned patients (Table 4).

**Table 1. Type of intoxication, and the route of the alcohol preparation of the methanol-poisoned patients**

|                                         | frequency (percentage) |          |
|-----------------------------------------|------------------------|----------|
| <b>Type of Intoxication</b>             | Incidental             | 39(86.7) |
|                                         | Unknown                | 6(13.3)  |
|                                         | Alcohol Dealer         | 17(37.8) |
|                                         | Unknown                | 17(37.8) |
| <b>The route of alcohol preparation</b> | Illegal Seller         | 6(13.3)  |
|                                         | Cosmetics Store        | 2(4.4)   |
|                                         | Peddler                | 2(4.4)   |
|                                         | Drug store             | 1(2.2)   |

**Table 2. Clinical presentations, underlying diseases, and outcomes of the methanol-poisoned patients**

|                                             | Variables                                    | Frequency (%) |          |
|---------------------------------------------|----------------------------------------------|---------------|----------|
| <b>Chief complain</b>                       | Seizure                                      | 3(6.7)        |          |
|                                             | Impaired Consciousness                       | 25(55.6)      |          |
|                                             | Nausea and Vomiting                          | 21(46.7)      |          |
|                                             | Alcohol Breath                               | 17(37.8)      |          |
|                                             | Gastric Pain                                 | 10(22.2)      |          |
|                                             | Shortness of Breath                          | 6(13.3)       |          |
|                                             | Visual Impairment                            |               | 26(57.8) |
| <b>Vision Acuity</b>                        | blurred vision                               | 16(35.6)      |          |
|                                             | Scotoma                                      | 2(4.4)        |          |
|                                             | Halos Vision                                 | 2(4.4)        |          |
|                                             | Color Vision Deficiency                      | 1(2.2)        |          |
|                                             | Others                                       | 5(11.1)       |          |
|                                             | Normal                                       | 13(28.9)      |          |
|                                             | Counting fingers                             | 2(4.4)        |          |
| <b>Status of Pupils</b>                     | Hand Motion                                  | 2(4.4)        |          |
|                                             | Light Perception                             | 1(2.2)        |          |
|                                             | Light Imperceptions                          | 1(2.2)        |          |
|                                             | Un-assessable                                | 8(17.8)       |          |
|                                             | Normal                                       | 12(26.7)      |          |
|                                             | Mydriasis                                    | 14(31.1)      |          |
|                                             | Miosis                                       | 7(15.6)       |          |
| <b>Underlying disease/<br/>co-morbidity</b> | Not Reactive to Light                        | 1(2.2)        |          |
|                                             | Un-assessable                                | 1(2.2)        |          |
|                                             | Hypertension                                 | 3(6.7)        |          |
|                                             | Diabetes Mellitus                            | 2(4.4)        |          |
|                                             | Seizure                                      | 2(4.4)        |          |
|                                             | Face Trauma                                  | 2(4.4)        |          |
|                                             | Psychological Complications                  | 1(2.2)        |          |
|                                             | Renal Lithiasis                              | 1(2.2)        |          |
|                                             | Chronic Kidney Disease (CKD)                 | 1(2.2)        |          |
|                                             | Cardiovascular Disease                       | 1(2.2)        |          |
|                                             | Chronic Obstructive Pulmonary Disease (COPD) | 1(2.2)        |          |
|                                             | Tramadol abuse                               | 1(2.2)        |          |
| <b>Outcome</b>                              | Opioid dependent                             | 2(4.4)        |          |
|                                             | Discharged                                   | 21(46.7)      |          |
|                                             | Death                                        | 16(35.6)      |          |
|                                             | Discharged by Personal Consent               | 8(17.8)       |          |

**Table 3. The association between patients' clinical manifestations and the risk of mortality in the methanol poisoned patients**

| variable                        | Outcome       | Comparing     |                  | PV        | Logistic regression |       |
|---------------------------------|---------------|---------------|------------------|-----------|---------------------|-------|
|                                 |               | Mean (SD)     | Median (Min-Max) |           | OR(95%CI)           | PV    |
| <b>GCS total</b>                | Survivors     | 13.16(2.14)   | 14.00( 8-15)     | <0.001NP  | 0.445(0.260-0.763)  | 0.003 |
|                                 | Non-survivors | 5.86(3.21)    | 4.5(3-13)        |           |                     |       |
|                                 | Total         | 10.54(4.36)   | 11.0(3-15)       |           |                     |       |
| <b>GCS (EYE)</b>                | Survivors     | 3.4(0.76)     | 4.00(2-4)        | <0.001    | 0.052(0.007-0.373)  | 0.003 |
|                                 | Non-survivors | 1.0(0.65)     | 1.00(1-3)        |           |                     |       |
|                                 | Total         | 2.72(1.17)    | 3.00(1-4)        |           |                     |       |
| <b>GCS (Verbal)</b>             | Survivors     | 4.12(0.971)   | 4.00(2-5)        | <0.001    | 0.147(0.044-0.495)  | 0.002 |
|                                 | Non-survivors | 1.79(1.051)   | 1.00(1-4)        |           |                     |       |
|                                 | Total         | 3.28(1.5)     | 3.00(1-5)        |           |                     |       |
| <b>GCS (Motor)</b>              | Survivors     | 5.60(0.707)   | 6.00(4-6)        | <0.001 NP | 0.184(0.066-0.509)  | 0.001 |
|                                 | Non-survivors | 2.57(1.604)   | 2.5(1-6)         |           |                     |       |
|                                 | Total         | 4.51(1.83)    | 5.00(1-6)        |           |                     |       |
| <b>Systolic blood pressure</b>  | Survivors     | 123.5(17.43)  | 120.00(90-160)   | 0.739 NP  | 1.006(0.979-1.035)  | 0.658 |
|                                 | Non-survivors | 127.0(34.84)  | 121.00(60.185)   |           |                     |       |
|                                 | Total         | 124.60(23.78) | 120.50(60-185)   |           |                     |       |
| <b>Diastolic blood pressure</b> | Survivors     | 76.34(11.17)  | 73.00 (55-110)   | 0.338     | 1.025(0.975-1.078)  | 0.334 |
|                                 | Non-survivors | 80.83(18.07)  | 80.00(50-120)    |           |                     |       |
|                                 | Total         | 77.66(13.47)  | 77.00(50-120)    |           |                     |       |
| <b>Pulse rate</b>               | Survivors     | 91.24(16.57)  | 88.00(60-126)    | 0.372 NP  | 1.018(0.987-1.050)  | 0.264 |
|                                 | Non-survivors | 99.38(29.96)  | 95.00(50-163)    |           |                     |       |
|                                 | Total         | 93.76(21.56)  | 89.00(50-163)    |           |                     |       |
| <b>Respiratory rate</b>         | Survivors     | 17.59(1.74)   | 18.00(12-21)     | 0.001     | 2.675(1.325- 5.395) | 0.006 |
|                                 | Non-survivors | 20.67(3.87)   | 20.00(17-32)     |           |                     |       |
|                                 | Total         | 18.49(2.87)   | 18.00(12-32)     |           |                     |       |

NP=Nan parametric test

**Table 4. Sensitivity and Specificity of different clinical and laboratory findings of methanol poisoned patients for mortality and brain CT findings**

| Variable                | prediction                       | Associated criterion | Sensitivity (95% CI)   | Specificity (95% CI) | + likelihood ratio (95% CI) | Area under the ROC curve (AUC) | Significance level P (Area=0.5) |
|-------------------------|----------------------------------|----------------------|------------------------|----------------------|-----------------------------|--------------------------------|---------------------------------|
| <b>GCS</b>              | mortality                        | ≤9                   | 85.71<br>(57.2-98.2)   | 96.00<br>(79.6-99.9) | 21.43<br>(3.10-147.97)      | 0.96                           | <0.0001                         |
| <b>Respiratory rate</b> | mortality                        | >19                  | 75.00<br>(42.8-94.5)   | 89.66<br>(72.6-97.8) | 7.25<br>(2.37-22.22)        | 0.83                           | <0.0001                         |
| <b>Creatinine</b>       | mortality                        | >1.8                 | 53.33<br>(26.6-78.7)   | 96.43<br>(81.7-99.9) | 14.93<br>(2.06-108.38)      | 0.82                           | <0.0001                         |
| <b>HCO3</b>             | mortality                        | ≤11.4                | 62.50<br>(35.4-84.8)   | 89.66<br>(72.6-97.8) | 6.04<br>(1.94-18.83)        | 0.77                           | 0.0016                          |
| <b>PH</b>               | mortality                        | ≤7.11                | 62.50<br>(35.4-84.8)   | 93.10<br>(77.2-99.2) | 9.06<br>(2.26-36.39)        | 0.76                           | 0.0052                          |
| <b>PCo2</b>             | Cerebellar Hypo-densities        | ≤32.4                | 100.00<br>(15.8-100.0) | 75.61<br>(59.7-87.6) | 4.10<br>(2.39-7.03)         | 0.76                           | 0.0001                          |
| <b>PCO2</b>             | CT finding                       | ≤36.2                | 71.43<br>(41.9-91.6)   | 68.97<br>(49.2-84.7) | 2.30<br>(1.22-4.35)         | 0.75                           | 0.0015                          |
| <b>PCO2</b>             | Diffuse Cerebral Hemorrhage      | ≤36.2                | 81.82<br>(48.2-97.7)   | 68.75<br>(46.8-81.4) | 2.62<br>(1.46-4.70)         | 0.78                           | 0.0005                          |
| <b>PCO2</b>             | Putamen Hypo-densities           | ≤34.4                | 83.33<br>(35.9-99.6)   | 77.78<br>(60.8-89.9) | 3.75<br>(1.85-7.61)         | 0.83                           | 0.0001                          |
| <b>PCO2</b>             | Subcortical White Matter Changes | ≤32.4                | 75.00<br>(34.9-96.8)   | 82.86<br>(66.4-93.4) | 4.38<br>(1.91-10.04)        | 0.84                           | <0.0001                         |
| <b>Potassium</b>        | mortality                        | >4.3                 | 75.00<br>(47.6-92.7)   | 88.89<br>(70.8-97.6) | 6.75<br>(2.24-20.35)        | 0.79                           | 0.0007                          |

**Table 5. The association between patients' laboratory data and the risk of mortality in the methanol poisoned patients**

| variable          | outcome       | Compare means |                    | Logisric regression |                          |       |
|-------------------|---------------|---------------|--------------------|---------------------|--------------------------|-------|
|                   |               | Mean(SD)      | Median(Min-Max)    | PV                  | OR(95%CI)                | PV    |
| <b>Creatinine</b> | Survivors     | 1.03(0.440)   | 0.900(0.5-2.4)     | 0.007 NP            | 6.258(1.59-24.58)        | 0.009 |
|                   | Non-survivors | 2.26(1.58)    | 1.85(0.8-6.0)      |                     |                          |       |
|                   | Total         | 1.48(1.16)    | 1.05(0.5-6.0)      |                     |                          |       |
| <b>Urea</b>       | Survivors     | 30.25(13.64)  | 29.5(10-66)        | 0.089 NP            | 1.03(0.993-1.069)        | 0.109 |
|                   | Non-survivors | 60.62(66.28)  | 35.00(14-250)      |                     |                          |       |
|                   | Total         | 41.30(43.12)  | 29.50(10-250)      |                     |                          |       |
| <b>sodium</b>     | Survivors     | 140.1(3.16)   | 140.00(135-149)    | 0.708 NP            | 0.972(0.864-1.094)       | 0.637 |
|                   | Non-survivors | 139.25(8.31)  | 140.00(128-163)    |                     |                          |       |
|                   | Total         | 139.80(5.56)  | 140.00(128-163)    |                     |                          |       |
| <b>potassium</b>  | Survivors     | 4.02(0.69)    | 4.00(3-6.7)        | 0.001               | 3.672(1.443-9.345)       | 0.006 |
|                   | Non-survivors | 4.95(1.03)    | 4.90(3.6-60)       |                     |                          |       |
|                   | Total         | 4.36(0.94)    | 4.20(3-6.70)       |                     |                          |       |
| <b>calcium</b>    | Survivors     | 8.74(0.48)    | 8.80(8.0-9.6)      | 0.63 NP             | 0.170(0.29-0.992)        | 0.49  |
|                   | Non-survivors | 7.75(1.13)    | 7.5(6.0-9.6)       |                     |                          |       |
|                   | Total         | 8.37(0.90)    | 8.50(6.0-9.6)      |                     |                          |       |
| <b>Glucose</b>    | Survivors     | 123.5(52.78)  | 111.50(64.0-287.0) | 0.031 NP            | 1.011(1.002-1.020)       | 0.019 |
|                   | Non-survivors | 193.0(108.10) | 108.0(49.0-365.0)  |                     |                          |       |
|                   | Total         | 148.92(83.52) | 115.0(49.0-365.0)  |                     |                          |       |
| <b>PH</b>         | Survivors     | 7.29(0.11)    | 7.31(70.5-7.45)    | 0.004 NP            | 0.001(0.000015 - 0.1.09) | 0.003 |
|                   | Non-survivors | 7.05(0.28)    | 7.06(6.61-7.48)    |                     |                          |       |
|                   | Total         | 7.21(0.22)    | 7.28(6.61-7.48)    |                     |                          |       |
| <b>PCO2</b>       | Survivors     | 42.49(13.75)  | 39.30(14.1-78.4)   | 0.302               | 0.978(0.938-1.021)       | 0.314 |
|                   | Non-survivors | 37.73(17.58)  | 38.2(9.8-70.9)     |                     |                          |       |
|                   | Total         | 40.79(15.15)  | 39.30(9.8-70.9)    |                     |                          |       |
| <b>HCO3</b>       | Survivors     | 21.13(6.78)   | 22.10(4.00-29.1)   | 0.001               | 0.872(0.797-0.953)       | 0.003 |
|                   | Non-survivors | 12.34(8.95)   | 8.85(2.7-30.6)     |                     |                          |       |
|                   | Total         | 18.00(8.64)   | 1940(2.70-29.1)    |                     |                          |       |

NP=Nan parametric test

**Table 6. Frequency of Brain CT scan findings of the methanol poisoned patients and the relationship with mortality**

| CT-scan findings                        | Number (%) | OR (95%CI)          | P-Value |
|-----------------------------------------|------------|---------------------|---------|
| <b>Abnormal Brain CT-scan Findings</b>  | 15(33.33)  | 4.929(1.297-18.733) | 0.019   |
| <b>Diffuse Cerebral Hemorrhage</b>      | 12(26.66)  | 3.733(0.939-14.837) | 0.061   |
| <b>Subcortical White Matter Changes</b> | 9(20)      | 2.841(0.638-12.654) | 0.171   |
| <b>Putamen Hypo-densities</b>           | 7(15.55)   | 2.889(0.557-14.980) | 0.206   |
| <b>Intra Cranial Hemorrhage</b>         | 4(8.88)    | 1.929(0.245-15.185) | 0.533   |
| <b>Putamen Hemorrhage</b>               | 3(6.66)    | 0.900(0.075-10769)  | 0.934   |
| <b>Cerebellar Hypo-densities</b>        | 2(4.44)    | 1.867(0.109-32.009) | 0.667   |

OR=Odds ratio for mortality, CI= 95% Confidence interval

**Table 7. The association between patients' clinical manifestations and laboratory data with the risk of positive brain CT findings in the methanol poisoned patients**

| variable                        | CT finding | Compare means |                    | PV       | Logistic regression |       |
|---------------------------------|------------|---------------|--------------------|----------|---------------------|-------|
|                                 |            | Mean(SD)      | Median(Min-Max)    |          | B(CI)               | PV    |
| <b>GCS</b>                      | Positive   | 9.58(4.21)    | 9.50(3-15)         | 0.368    | 0.929(0.795-1.09)   | 0.359 |
|                                 | Negative   | 10.96(4.33)   | 13.00(3-15)        |          |                     |       |
| <b>Systolic blood pressure</b>  | Positive   | 136.21(26.97) | 130.50(100-185)    | 0.023    | 1.037(1.003-1.072)  | 0.035 |
|                                 | Negative   | 118.79(20.1)  | 12.00(60-160)      |          |                     |       |
| <b>Diastolic blood pressure</b> | Positive   | 80.36(19.26)  | 78.50(50-120)      | 0.463 NP | 1.023(0.974-1.074)  | 0.358 |
|                                 | Negative   | 76.26(9.35)   | 75.00(55-95)       |          |                     |       |
| <b>Pulse rate</b>               | Positive   | 103.29(24.53) | 95.00(78-163)      | 0.041    | 1.034 (0.999-1.071) | 0.059 |
|                                 | Negative   | 89.0(18.59)   | 88.00(20-126)      |          |                     |       |
| <b>Respiratory rate</b>         | Positive   | 19.36(3.84)   | 18.00(12-23)       | 0.166    | 1.192(0.906-1.568)  | 0.211 |
|                                 | Negative   | 18.04(2.18)   | 18.00(16-32)       |          |                     |       |
| <b>Creatinine</b>               | Positive   | 1.62(1.01)    | 1.30(0.6-4.2)      | 0.583    | 1.161(0.688-1.960)  | 0.577 |
|                                 | Negative   | 1.41(1.25)    | 1.00(0.5-6.0)      |          |                     |       |
| <b>Urea</b>                     | Positive   | 37.80(20.99)  | 30.0(10-86)        | 0.704    | 0.997(0.981-1.013)  | 0.699 |
|                                 | Negative   | 43.13(51.23)  | 29.00(10.0-250.0)  |          |                     |       |
| <b>sodium</b>                   | Positive   | 138.4(8.18)   | 137.00(128-163)    | 0.243    | 0.922(0.803-1.057)  | 0.244 |
|                                 | Negative   | 140.5(3.56)   | 141.00(132-149)    |          |                     |       |
| <b>potassium</b>                | Positive   | 4.45(1.05)    | 4.15(3-6.60)       | 0.682    | 1.154(0.592-2.251)  | 0.675 |
|                                 | Negative   | 4.32(0.89)    | 4.60(3.0-6.7)      |          |                     |       |
| <b>calcium</b>                  | Positive   | 8.67(0.72)    | 8.65(7.5-9.6)      | 0.551    | 1.480(0.434-5.027)  | 0.530 |
|                                 | Negative   | 8.29(0.98)    | 8.50(6.0-9.6)      |          |                     |       |
| <b>Glucose</b>                  | Positive   | 164.07(96.95) | 118(83-365)        | 0.410    | 1.0003(0.996-1.011) | 0.402 |
|                                 | Negative   | 141.07(76.46) | 112.0(49-315)      |          |                     |       |
| <b>PH</b>                       | Positive   | 7.176(0.234)  | 7.21(6.71-7.48)    | 0.522    | 0.390(0.023-6.570)  | 0.514 |
|                                 | Negative   | 7.221(0.211)  | 7.30(6.61-7.45)    |          |                     |       |
| <b>PCO2</b>                     | Positive   | 33.04(12.65)  | 34.40(9.80-52.60)  | 0.013    | 0.940(0.892-0.991)  | 0.022 |
|                                 | Negative   | 44.68(14.99)  | 42.55(17.30-78.40) |          |                     |       |
| <b>HCO3</b>                     | Positive   | 14.21(9.10)   | 17.00(3.40-30.60)  | 0.036    | 0.923(0.854-0.997)  | 0.042 |
|                                 | Negative   | 19.90(7.87)   | 21.250(2.70-32.40) |          |                     |       |

NP=Non parametric test



## Discussion

The current study was conducted on methanol-poisoned patients to verify the association between clinical presentations and brain CT scan findings. All patients in the current study were poisoned after consuming alcoholic beverages, with the main complaints of visual and consciousness impairment, nausea, and vomiting, respectively. Visual impairment affected about 60% of the patients. Among them, 61.5% stated that they have blurred vision. Prevalence of various presentations in the current study (Table 2) is similar to Mahdavi et al., study that was a multi-center study on methanol poisoned cases from all parts of Iran (8). In a review study, blurred vision combined with intact consciousness was identified as a strong indicator of methanol intoxication (23). The visual acuity in the most cases of the current research was normal (28.9%). Considering the pupils' status, most patients had mydriasis, consistent with multiple studies reporting mydriasis, including delayed or non-reactive mydriasis to light, as a common presentation in Methanol-poisoned cases (23-25). Ocular symptoms of methanol poisoning are considered the consequence of retinal and optic nerve damage caused by the inhibition of cytochrome oxidase activity and mitochondrial impairment (26,27).

In our study, lower GCS levels were significantly associated with fatal outcomes (OR=0.445). Other studies also mentioned that a lower GCS<8-9 is a predictor of poor prognosis in methanol-poisoned patients (6,8,22,23,28).

According to our results, the higher levels of creatinine, potassium, glucose, and lower levels of PH and bicarbonate were associated with higher mortality risk, consistent with previous cross-sectional studies (16, 22,23,28,29). In a case series study of 51 methanol-poisoned patients from Norway, severe metabolic acidosis (pH<6.90, base defect>28 mmol/L), and elevated pCO<sub>2</sub> level were significant predictors of poor prognosis in these cases (6). The difference in the predictive role of PCO<sub>2</sub> might be due to the differing mean levels between our study and the Norwegian study (52.62 mmHg vs. 99.75 mmHg). Respiratory arrest, hyperglycemia, and delayed hospital admission were recognized as risk factors for poor prognosis in methanol-poisoned patients in a retrospective cross-sectional study conducting in Sanandaj, Iran, over eight years (30). Interestingly, a study from Iran on 95 methanol-poisoned patients over seven years claimed that hyperglycemia could be a valuable prognostic factor (31) which was in line with our finding that higher blood glucose was

associated with fatal outcomes .

A study from the Czech Republic on 46 methanol-poisoned patients announced the higher prevalence of hemorrhagic brain lesions among radiological abnormalities, which was similar to our study. They mentioned that those with hemorrhagic brain lesions were more acidemic and had higher levels of glycemia and lactacidemia on admission than those without hemorrhages (32).

Regarding the guidelines, subjects with serum methanol levels higher than 20 mg/dl are considered as methanol-poisoned patients (27). In our study, the mean detected methanol level was 21.12±33.11 mg/dL, less than previous studies (6,29,33). Although high blood methanol levels were regarded as poor prognostic factors in a retrospective case series study of 147 methanol-poisoned patients in Estonia (34), it could not be counted as a prognostic factor according to some other investigations (22,23). This disparity can be explained by different ingested methanol amounts and delay hospital admission. Since methanol is metabolized to formic acid over time, serum methanol levels may not accurately reflect the severity of toxicity (35). Formic acid is a sensitive marker for methanol poisoning confirmation. While formic acid levels≥50 mg/dl have been linked to extreme toxicity, a 90% mortality risk has been pointed out in patients with≥315 mg/dl formic acid (2,36).

Hemodialysis may reduce the patient's hospital stay through elimination of methanol and formic acid and correcting metabolic acidosis (37). In the current study, 40% of patients underwent emergency dialysis, while 15.6% underwent second-time hemodialysis. In a cross-sectional study of 795 methanol-poisoned patients from different provinces of Iran during the COVID-19 pandemic, a higher rate of second-time hemodialysis was found in non-survivor than survivor groups (8). In a retrospective study on 30 methanol-poisoned patients in Tehran, Iran, 14(46%) had undergone hemodialysis by the median time interval of 4 hours after hospitalization, of whom four patients died. However, no significant association was found between hemodialysis and patient outcomes (7). In another retrospective cohort study from the U.S. on 603 methanol-poisoned patients, about 40% needed life-supporting treatments for renal failures, such as hemodialysis (38).

In the present study, most patients had normal CT findings, but among those with abnormalities, diffuse cerebral hemorrhage was the most prevalent, followed by subcortical white matter changes and putamen hypodensities. We observed a significant correlation between abnormal brain CT findings and the methanol

poisoning mortality rate (OR=4.929), while none of the specific CT findings was associated with a higher risk of mortality. Previous studies have reported distinctive brain radiological manifestations in methanol intoxication, including brain and cerebellar edema, subarachnoid and intracerebral hemorrhage, putaminal and cerebral white matter hypodensities, and focal lesions in the cerebellum, globus pallidus, and hypothalamus (15-17,39,40). Basal ganglion necrosis is now acknowledged as the most radiological characteristic presentation in methanol-poisoned patients (41-43), especially the putamen (hemorrhagic or non-hemorrhagic) necrosis that has been widely reported as a CT and/or MRI manifestation (21,44,45). In a cross-sectional study from Iran, 40 patients out of 516 participants underwent CT scanning, and it was declared that the putaminal or subcortical white matter hemorrhage could be regarded as a mortality indicator in methanol-poisoned patients (22). Also, a cohort study in Iran on 42 methanol-poisoned patients reported bilateral putaminal hypodensity as the most common CT presentation and insisted that there was a significant association between necrosis of insular subcortex white matter and putaminal hemorrhage and the poor prognosis of methanol poisoning (16). Surprisingly, a case report of methanol toxicity from Turkey did not present any pathological feature of the basal ganglia MRI (46).

In the current study, we assessed the association of clinical manifestations, laboratory findings, and radiological presentations with mortality due to methanol poisoning. It was revealed that lower GCS (<9), higher respiratory rate (>19 cycles/min), higher levels of creatinine (1.8mg/dl), potassium (4.3 mEq/L), and glucose, and lower levels of PH (<7.11) and bicarbonate (<11.4 mEq/L) could be considered key indicators of mortality with efficient sensitivity and specificity. The presence of abnormal brain CT findings was associated with a higher mortality risk (4.929), but none of the specific CT findings was associated with fatal outcomes. These findings can help physicians in the early and effective triage and treatment of methanol-poisoned patients based on their clinical and subclinical manifestations. The high prevalence of methanol poisoning in Iran and the paucity of research on this topic highlight the necessity of conducting further large-scale studies to explain the prognostic factors in methanol poisoning.

## Limitations

Although our study had several strengths, including

there were some limitations in this study.

The osmolar gap and formic acid levels were not evaluated due to a lack of laboratory equipment, even though they were reported as valuable indicators (2,35).

The retrospective cross-sectional design of the study may limit the ability to establish causality between variables, and future studies would benefit from a prospective design. However, nearly all of the similar studies were done retrospectively (7,16,29,30,32,39).

Despite the availability of data for most of the patients, the long-term outcomes of patients could not be determined as it was a cross-sectional study.

We only evaluated the clinical, paraclinical, and outcome of the patients who have undergone the brain CT scan, thus we mostly evaluated moderate to severe cases.

## Acknowledgments

The data reported in this article are part of an M.D. thesis. We would also like to thank the staff of CTD-IRH-MUMS for their warm cooperation.

## References

1. Blug M, Leker J, Plass L, Günther A. Methanol generation economics. In: *Methanol: The basic chemical and energy feedstock of the future*. Springer; 2014:603-18.
2. Kraut JA. Approach to the treatment of methanol intoxication. *Am J Kidney Dis* 2016;68:161-7.
3. Barceloux DG, Bond GR, Krenzelok EP, Cooper H, Vale JA, American Academy of Clinical Toxicology Ad Hoc Committee on the Treatment Guidelines for Methanol Poisoning. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. *J Toxicol Clin Toxicol* 2002;40:415-46.
4. Lushine KA, Harris CR, Holger JS. Methanol ingestion: prevention of toxic sequelae after massive ingestion. *J Emerg Med* 2003;24:433-6.
5. Eghbali H, Mostafazadeh B, Ghorbani M, Behnoush B. Neurologic complications of methanol poisoning: a clinicoepidemiological report from poisoning treatment centers in Tehran, Iran. *Asia Pac J Med Toxicol* 2015;4:47-50.
6. Hovda KE, Hunderi OH, Tafjord AB, Dunlop O, Rudberg N, Jacobsen D. Methanol outbreak in Norway 2002-2004: epidemiology, clinical features and prognostic signs. *J Intern Med* 2005;258:181-90.
7. Shadnia S, Rahimi M, Soltaninejad K, Nilli A. Role of clinical and paraclinical manifestations of methanol poisoning in outcome prediction. *J Res Med Sci* 2013;18:865-9.

8. Mahdavi SA, Zamani N, McDonald R, Akhgari M, Kolahi AA, Gheshlaghi F, et al. A cross-sectional multicenter linkage study of hospital admissions and mortality due to methanol poisoning in Iranian adults during the COVID-19 pandemic. *Sci Rep* 2022;12:9741.
9. Mehrpour O, Sadeghi M. Toll of acute methanol poisoning for preventing COVID-19. *Arch Toxicol* 2020;94:2259-60.
10. Mostafazadeh B, Eghbali H. An epidemiologic study on methyl alcohol poisoning in Tehran, Iran. *Asia Pac J Med Toxicol* 2014;3:8.
11. Shokoohi M, Nasiri N, Sharifi H, Baral S, Stranges S. A syndemic of COVID-19 and methanol poisoning in Iran: time for Iran to consider alcohol use as a public health challenge? *Alcohol* 2020;87:25-7.
12. Mahdavi SA, Kolahi AA, Akhgari M, Gheshlaghi F, Gholami N, Moshiri M, et al. COVID-19 pandemic and methanol poisoning outbreak in Iranian children and adolescents: a data linkage study. *Alcohol Clin Exp Res* 2021;45:1853-63.
13. Ahmed F, Khan NU, Ali N, Feroze A. Methanol poisoning: 27 years experience at a tertiary care hospital. *J Pak Med Assoc* 2017;67:1751-2.
14. Mousavi SR, Dadpour B, Moshiri M, Moghiman T, Khosrojerdi H, Najari F. Methanol poisoning as a trigger for the presentation of diabetes mellitus: a case report. *Int J Med Toxicol Forensic Med* 2019;9:151-4.
15. Camurcuoglu E, Halefoglu AM. CT and MR imaging findings in methanol intoxication manifesting with bilateral severe basal ganglia and cerebral involvement. *J Belg Soc Radiol* 2022;106:66.
16. Taheri MS, Moghaddam HH, Moharamzad Y, Dadgari S, Nahvi V. The value of brain CT findings in acute methanol toxicity. *Eur J Radiol* 2010;73:211-4.
17. Bessell-Browne R, Bynevelt M. Two cases of methanol poisoning: CT and MRI features. *Australas Radiol* 2007;51:175-8.
18. Kim HJ, Na JY, Lee YJ, Park JT, Kim HS. An autopsy case of methanol induced intracranial hemorrhage. *Int J Clin Exp Pathol* 2015;8:13643-6.
19. Hassanian-Moghaddam H, Bahrami-Motlagh H, Zamani N, Fazeli SA, Behnam B. Intracranial hemorrhage in methanol toxicity: challenging the probable heparin effect during hemodialysis. *J Res Pharm Pract* 2017;6:186-9.
20. Sohor NJ, Loh WC, Pang RY, Khan AH, Chia PK, Sulaiman WAW, et al. Spontaneous bilateral basal ganglia haemorrhage secondary to methanol poisoning. *Neurol India* 2023;71:1260-2.
21. Arora V, Nijjar IB, Multani AS, Singh JP, Abrol R, Chopra R, et al. MRI findings in methanol intoxication: a report of two cases. *Br J Radiol* 2007;80:e243-6.
22. Simani L, Ramezani M, Roozbeh M, Shadnia S, Pakdaman H. The outbreak of methanol intoxication during COVID-19 pandemic: prevalence of brain lesions and its predisposing factors. *Drug Chem Toxicol* 2022;45:1500-3.
23. Nekoukar Z, Zakariaei Z, Taghizadeh F, Musavi F, Banimostafavi ES, Sharifpour A, et al. Methanol poisoning as a new world challenge: a review. *Ann Med Surg (Lond)* 2021;66:102445.
24. Sharma R, Marasini S, Sharma AK, Shrestha JK, Nepal BP. Methanol poisoning: ocular and neurological manifestations. *Optom Vis Sci* 2012;89:178-82.
25. Koehrer P, Creuzot-Garcher C, Bron AM. Methanol poisoning: two case studies of blindness in Indonesia. *Int Ophthalmol* 2011;31:517-24.
26. Grzybowski A, Zulsdorff M, Wilhelm H, Tonagel F. Toxic optic neuropathies: an updated review. *Acta Ophthalmol* 2015;93:402-10.
27. Baj J, Forma A, Kobak J, Tyczyńska M, Dudek I, Maani A, et al. Toxic and nutritional optic neuropathies: an updated mini-review. *Int J Environ Res Public Health* 2022;19.
28. Paasma R, Hovda KE, Hassanian-Moghaddam H, Brahmi N, Afshari R, Sandvik L, et al. Risk factors related to poor outcome after methanol poisoning and the relation between outcome and antidotes: a multicenter study. *Clin Toxicol (Phila)* 2012;50:823-31.
29. Hassanian-Moghaddam H, Pajoumand A, Dadgar SM, Shadnia S. Prognostic factors in methanol poisoning. *Hum Exp Toxicol* 2007;26:583-6.
30. Yousefinejad V, Moradi B, Mohammadi Baneh A, Sheikhesmaeili F, Babahajian A. Prognostic factors of outcome in methanol poisoning: an 8-year retrospective cross-sectional study. *Arch Acad Emerg Med* 2020;8:e69.
31. Sanaei-Zadeh H, Kazemi Esfeh S, Zamani N, Jamshidi F, Shadnia S. Hyperglycemia is a strong prognostic factor of lethality in methanol poisoning. *J Med Toxicol* 2011;7:189-94.
32. Zakharov S, Kotikova K, Vaneckova M, Seidl Z, Nurieva O, Navratil T, et al. Acute methanol poisoning: prevalence and predisposing factors of haemorrhagic and non-haemorrhagic brain lesions. *Basic Clin Pharmacol Toxicol* 2016;119:228-38.
33. Kerns W 2nd, Tomaszewski C, McMartin K, Ford M, Brent J, Alcohols Study Group, Multicenter Methanol Treatment Trial. Formate kinetics in methanol poisoning. *J Toxicol Clin Toxicol* 2002;40:137-43.
34. Paasma R, Hovda KE, Tikkerberi A, Jacobsen D. Methanol mass poisoning in Estonia: outbreak in 154 patients. *Clin Toxicol (Phila)* 2007;45:152-7.
35. Hovda KE, Hunderi OH, Rudberg N, Froyshov S, Jacobsen D. Anion and osmolal gaps in the diagnosis of methanol

- poisoning: clinical study in 28 patients. *Intensive Care Med* 2004;30:1842-6.
36. Kubán P, Foret F, Bocek R. Capillary electrophoresis with contactless conductometric detection for rapid screening of formate in blood serum after methanol intoxication. *J Chromatogr A* 2013;1281:142-7.
  37. Lachance P, Mac-Way F, Desmeules S, De Serres SA, Julien AS, Douville P, et al. Prediction and validation of hemodialysis duration in acute methanol poisoning. *Kidney Int* 2015;88:1170-7.
  38. Kaewput W, Thongprayoon C, Petnak T, Chewcharat A, Boonpheng B, Bathini T, et al. Inpatient burden and mortality of methanol intoxication in the United States. *Am J Med Sci* 2021;361:69-74.
  39. Sefidbakht S, Rasekhi AR, Kamali K, Borhani Haghighi A, Salooti A, Meshksar A, et al. Methanol poisoning: acute MR and CT findings in nine patients. *Neuroradiology* 2007;49:427-35.
  40. Vaneckova M, Zakharov S, Klempir J, Ruzicka E, Bezdicek O, Brozova H, et al. Imaging findings after methanol intoxication (cohort of 46 patients). *Neuro Endocrinol Lett* 2015;36:737-44.
  41. Anderson JC, Costantino MM, Stratford T. Basal ganglia: anatomy, pathology, and imaging characteristics. *Curr Probl Diagn Radiol* 2004;33:28-41.
  42. Mana J, Vaneckova M, Klempir J, Lišková I, Brožová H, Poláková K, et al. Methanol poisoning as an acute toxicological basal ganglia lesion model: evidence from brain volumetry and cognition. *Alcohol Clin Exp Res* 2019;43:1486-97.
  43. Çomoğlu S, Özen B, Özbakır Ş. Methanol intoxication with bilateral basal ganglia infarct. *Australas Radiol* 2001;45:357-8.
  44. Sanaei-Zadeh H. Typical bilateral putaminal lesions of methanol intoxication. *J Emerg Med*. 2012;42(2):178-9.
  45. Dujardin M, Peeters E, Ernst C, Stadnik T. Bilateral putaminal necrosis due to methanol abuse. *JBR BTR* 2006;89:316.
  46. Tanrivermis Sayit A, Aslan K, Elmali M, Gungor I. Methanol-induced toxic optic neuropathy with diffusion weighted MRI findings. *Cutan Ocul Toxicol* 2016;35:337-40.